BayBio presents a morning seminar on alternative fundraising strategies for biotech startups. From the event description:
“For life science companies facing lengthy, high-cost R&D cycles, government approvals, and difficult clinical trials, funding is their lifeblood. Of course, there’s less money to go around these days with the IPO market essentially having grinded to a halt and the competition for VC funding fierce. Fortunately, there are other sources.
This panel discussion will cover some of the lesser-known funding options available in today’s marketplace. Accounting, finance, and legal considerations surrounding these alternatives will be discussed in detail. In addition, experts working at venture capital and Super Angel firms, to provide their perspectives and insights.
The following areas will be addressed:
- Private Investments in Public Securities (PIPEs)
- Reverse mergers
- Super Angel funding
- Smaller venture capital rounds
- Foreign investor financings
- Federal government grants
Moderator: Michael Benjamin, Shareholder, Burr Pilger Mayer, Inc.
Speakers
Larry Gerrans, President & CEO, Sanovas
Jerry Iwata, Vice President, Wells Fargo Bank
Bruce W. Jenett, Partner and Co-Chair, Global Life Sciences Sector DLA Piper
Michael Powell, PhD, General Partner, Sofinnova Ventures
Kim Tsuchimoto, Chief Financial Officer, Treasurer and Secretary Raptor Pharmaceutical Corporation”